When electronic prescriptions were first introduced, they were supposed to be more convenient for patients and cause less errors at the pharmacy (due to the legible nature of the information being sent from the prescriber).
PAAS National® continues to see auditors flag insulin pen prescriptions for containing a dosage that does not align with the product.
Insurance companies require pharmacies to bill an accurate days’ supply based on mathematical calculations from the directions.
Many pharmacies struggle with DMEPOS audits due to the complexity in medical billing and the onerous documentation requirements.
PAAS National® has seen an increase in prescription validation requests and audits for EpiPen® and, with back-to-school in full swing, we want all pharmacy employees to be aware of potential billing issues for this life-saving medication.
Many pharmacies struggle with DMEPOS audits due to the complexity in medical billing and the onerous documentation requirements.
DAW code billing on multi-source brand medications is a frequent audit target for PBMs due to their potential higher cost, change in pharmacy reimbursement, and impact on patient copays. PAAS National® recommends …
Unfortunately, the cost difference can be significant, leading to an increased risk for audit – especially when a patient is taking Glumetza® or Fortamet®.
PAAS National® is starting to see more audit recoupments on claims where a diagnosis code was required at adjudication but there was no documentation on the hardcopy to support the diagnosis code billed.
This DMEPOS series is intended to help you understand these complexities and gather the needed documents. In particular, you should be able to show the following if audited on surgical dressings…
